ONYX PHARMACEUTICALS, INC.
CALCULATION OF NET REVENUE FROM UNCONSOLIDATED JOINT BUSINESS
(In thousands, unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------ ------------------
2008 2007 2008 2007
-------- ------- -------- --------
Nexavar product revenue, net
(as recorded by Bayer) $180,887 $104,605 $501,303 $246,817
======== ======== ======== ==========
Revenue subject to profit
sharing (as recorded
by Bayer) $168,141 $104,605 $476,584 $246,817
Combined cost of goods sold,
distributed, selling, general
and administrative expenses 79,362 55,950 222,200 141,684
Combined research and
development expenses 41,855 37,561 123,279 105,707
Combined collaboration profit -------- ------- -------- --------
(loss) $46,924 $11,094 $131,105 $(574)
======== ======== ======== ==========
Onyx's share of collaboration
profit (loss) $23,462 $5,547 $65,553 $(287)
Reimbursement of Onyx's direct
development and marketing
expenses 15,570 12,088 40,577 28,418
Royalty revenue 892 - 1,730 -
Onyx net revenue from -------- ------- -------- --------
unconsolidated joint
business $39,924 $17,635
'/>"/>
| SOURCE Onyx Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |